Workshops

eHealth workshop - 8 April 2014 - Brussels

1. Agenda
2. Presentation from T. Piha: EU Commission strategy
3. Presentation from A. Mukherjee: Industry perspective
4. Presentation from M. Malik: ESC progress
5. Presentation from J. Cleland: ESC challenges

R&D workshop "Innovative design of clinical trials" - 13 & 14 March 2014 - Brussels

1. Agenda
2. Presentation from A. Svensson: Impediments to adoption of new therapies
3. Presentation from T. Friede: New approaches to CV trials
4. Presentation from M. Landray: Novel methods of recruitment or data capture
5. Presentation from H. Naci: Including cost effectiveness to inform clinical practice
6. Presentation from P. Mol: Treatments in development

"Obesity and CV impact" regulatory workshop - 03 October 2013 - London

1. Agenda
2. Presentation from G. Fruhbeck: Burden of obesity
3. Presentation from K. Clement: Pathophysiology of Obesity and Cardiovascular Diseases
4. Presentation from G. Bray: Overview of Therapeutic Strategies to Reduce Weight
5. Presentation from G. Fruhbeck: Healthy versus non-healthy
6. Presentation from B.L. Heitmann: Are there new ways to identify risk patients
7. Presentation from P. Valensi: ESC obesity CVD
8. Presentation from K. Dunder: Regulatory issues Obesity workshop 3 Oct
9. Presentation from C. Torp Pedersen: 2 Academic view weight loss trials
10. Presentation from R. Dvorak: CV safety and other final
11. Presentation from B. Van der Schueren: Regulatory view
12. Presentation from P. James: Benefit risk revisited 

"Comparative Effectiveness Research" workshop - 17 & 18 September 2013

1. Agenda
2. Presentation from J. Greenwood
3. Presentation from L. Shaw
4. Presentation from U. Hoffmann
5. Presentation from V. Dambrauskaite

"Personalised Medicine" workshop - 7 & 8 February 2013

 A European Society of Cardiology scientific policy workshop with the participation of academia and industry representatives

1. Agenda
2. Presentation from F. Kramer: Turning biomarkers into companion diagnostics
3. Presentation from H. Katus: Biomarkers to Guide management of MI.
4. Presentation from H. Schunkert: refinement of the SCORE by genetic information
5. Presentation from K. Swedberg: Personalized vs person-centered
6. Presentation from P. Kirchhof: Personalising rhythm control therapy by timing of therapy
7. Presentation from M. Schwab: Pharmacogenomics
8. Presentation from S. Oertelt: Gender personalized Medicine
9. Presentation from S. Pocock: Statistical Cautions re the Allure of Personalised (stratified) Medicine
10. Presentation from S. Priori: Inherited arrhythmic diseases
11. Presentation from L. Wallentin: Personalization of treatment in AF


"Health-related Quality of Life as key outcome parameter in CV medicine" workshop - 16 & 17 October 2012

1. Agenda
2. Presentation from I. Ford: Statistical issues in interpreting HRQoL data
3. Presentation from I. Wiklund: Clinical Outcomes assessment - PROs
4. Presentation from J. Caro: Statistical issues in interpreting HRQoL data
5. Presentation from J. Paty: HRQoL CRT workshop
6. Presentation from J. Riley: HRQoL to inform disease management Guidelines
7. Presentation from K. Swedberg: Clinical outcomes assessments to revive feasibility of trials in CV
8. Presentation from M. Cowie: HRQoL to characterize risk benefit of therapies  


"Large Simple Study" workshop - 14 & 15 June 2012

1. Agenda
2. Presentation from M. Flather: Background LST workshop
3. Presentation from C. Granger: Background LST workshop
4. Presentation from C. Baigent: Clinical Research Experience
5. Presentation from P. Armstrong: Clinical Research Experience
6. Presentation from J. Mc Murray: Safety Perspective
7. Presentation from S. Pocock: Data monitoring
8. Presentation from A. Svensson: Safety issues
9. Presentation from A. Gomez Outes: EMA perspective
10. Presentation from N. Stockbridge: FDA perspective
11. Breakout session reports

Workshop on "Ethnicity and CVD - consequences for generalizing study results" - 10 February 2012


The manuscript from the regulatory workshop on "Ethnicity and CVD - consequences for generalizing study results" was published in the European Heart Journal in March 2013. See attached article.

1. Agenda
2. Introduction from A Alonso
3. Presentation from L Tavazzi: General Variation in Epidemiology for CHD, HF, HTN, Stroke
4. Presentation from J Marrugat: Genetic testing for coronary heart disease prevention in the US and Europe
5. Presentation from L Wallentin: Examples of ethnicity and geography issues in global clinical trials of ACS and AF
6. Presentation from F Zannad: Study populations - Ethnic differences - intrinsic and extrinsic factors: What impact in Heart Failure outcome trials?
7. Presentation from A Svensson: Industry perspective: Ethnicity, Regions and Populations
8. Presentation from K Prasad: Ethnicity and CVD: Experience and difficulties encountered in some recent applications